Dyserythropoietic Anemia and Thrombocytopenia Overview
Learn About Dyserythropoietic Anemia and Thrombocytopenia
View Main Condition: Anemia
Dyserythropoietic anemia and thrombocytopenia is a condition that affects blood cells and primarily occurs in males. A main feature of this condition is a type of anemia called dyserythropoietic anemia, which is characterized by a shortage of red blood cells. The term "dyserythropoietic" refers to the abnormal red blood cell formation that occurs in this condition. In affected individuals, immature red blood cells are unusually shaped and cannot develop into functional mature cells, leading to a shortage of healthy red blood cells. People with dyserythropoietic anemia and thrombocytopenia can have another blood disorder characterized by a reduced level of circulating platelets (thrombocytopenia). Platelets are cells that normally assist with blood clotting. Thrombocytopenia can cause easy bruising and abnormal bleeding. While people with dyserythropoietic anemia and thrombocytopenia can have signs and symptoms of both blood disorders, some are primarily affected by anemia, while others are more affected by thrombocytopenia.
Mutations in the GATA1 gene cause dyserythropoietic anemia and thrombocytopenia. The GATA1 gene provides instructions for making a protein that attaches (binds) to specific regions of DNA and helps control the activity of many other genes. On the basis of this action, the GATA1 protein is known as a transcription factor. The GATA1 protein is involved in the specialization (differentiation) of immature blood cells. To function properly, these immature cells must differentiate into specific types of mature blood cells. Through its activity as a transcription factor and its interactions with other proteins, the GATA1 protein regulates the growth and division (proliferation) of immature red blood cells and platelet-precursor cells (megakaryocytes) and helps with their differentiation.
Dyserythropoietic anemia and thrombocytopenia is a rare condition; its prevalence is unknown. Occasionally, individuals with this disorder are mistakenly diagnosed as having more common blood disorders, making it even more difficult to determine how many people have dyserythropoietic anemia and thrombocytopenia.
This condition is inherited in an X-linked pattern. A condition is considered X-linked if the mutated gene that causes the disorder is located on the X chromosome, one of the two sex chromosomes in each cell. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. Because females have two copies of the X chromosome, one altered copy of the gene in each cell usually leads to less severe symptoms in females than in males or may cause no symptoms in females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.
Achille Iolascon practices in Naples, Italy. Mr. Iolascon is rated as an Elite expert by MediFind in the treatment of Dyserythropoietic Anemia and Thrombocytopenia. His top areas of expertise are Dyserythropoietic Anemia and Thrombocytopenia, Anemia, Hemolytic Anemia, Congenital Hemolytic Anemia, and Splenectomy.
Roberta Russo practices in Naples, Italy. Ms. Russo is rated as an Elite expert by MediFind in the treatment of Dyserythropoietic Anemia and Thrombocytopenia. Her top areas of expertise are Dyserythropoietic Anemia and Thrombocytopenia, Anemia, Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.
Cristian Tornador practices in Esplugues De Llobregat, Spain. Mr. Tornador is rated as an Elite expert by MediFind in the treatment of Dyserythropoietic Anemia and Thrombocytopenia. His top areas of expertise are Dyserythropoietic Anemia and Thrombocytopenia, Jaundice, Hyperferritinemia-Cataract Syndrome, and Anemia.
Summary: The investigators have created and maintain a comprehensive registry for patients with the diagnosis of Congenital Dyserythropoietic Anemia (CDA) in North America. The goal of this registry is to collect long-term confidential data on patients with CDA in the US, Canada, and Mexico and maintain a bio-repository of de-identified patient blood and bone marrow specimens as a tool for the investigatio...
Published Date: October 01, 2014
Published By: National Institutes of Health